Who are MMR Bio-Manguinhos's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Pentavalent rotavirus vaccine, Yellow fever vaccine, Institut Pasteur, Varicella Virus Vaccine Live, Bacillus Calmette-Guerin (BCG), Bacille Calmette Guerin (BCG), varicella-5.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/mmr-bio-manguinhos.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

MMR Bio-Manguinhos — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

MMR Bio-Manguinhos (MMR Bio-Manguinhos) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Live attenuated vaccine. Area: Immunology / Infectious Disease.

phase 3 Live attenuated vaccine Immunology / Infectious Disease Biologic Live · refreshed every 30 min

Target snapshot

MMR Bio-Manguinhos (MMR Bio-Manguinhos) — The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz). MMR Bio-Manguinhos is a live attenuated vaccine that stimulates immune responses against measles, mumps, and rubella viruses.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
MMR Bio-Manguinhos TARGET	MMR Bio-Manguinhos	The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)	phase 3	Live attenuated vaccine
Pentavalent rotavirus vaccine	Pentavalent rotavirus vaccine	Sanofi Pasteur, a Sanofi Company	marketed	Live attenuated vaccine
Yellow fever vaccine, Institut Pasteur	Yellow fever vaccine, Institut Pasteur	University of Oxford	marketed	Live attenuated vaccine
Varicella Virus Vaccine Live	Varicella Virus Vaccine Live	Sanofi Pasteur, a Sanofi Company	marketed	Live attenuated vaccine	Varicella-zoster virus (VZV)
Bacillus Calmette-Guerin (BCG)	Bacillus Calmette-Guerin (BCG)	Massachusetts General Hospital	marketed	Live attenuated vaccine / Immunotherapy
Bacille Calmette Guerin (BCG)	Bacille Calmette Guerin (BCG)	Bandim Health Project	marketed	Live attenuated vaccine
varicella-5	varicella-5	Changchun Keygen Biological Products Co., Ltd.	marketed	Live attenuated vaccine	Varicella-zoster virus

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Live attenuated vaccine class)

GlaxoSmithKline · 19 drugs in this class
Merck Sharp & Dohme LLC · 11 drugs in this class
Sanofi Pasteur, a Sanofi Company · 9 drugs in this class
PATH · 5 drugs in this class
Sanofi · 5 drugs in this class
Bandim Health Project · 5 drugs in this class
Centers for Disease Control and Prevention · 3 drugs in this class
International Centre for Diarrhoeal Disease Research, Bangladesh · 3 drugs in this class
Beijing Center for Disease Control and Prevention · 2 drugs in this class
Aga Khan University · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). MMR Bio-Manguinhos — Competitive Intelligence Brief. https://druglandscape.com/ci/mmr-bio-manguinhos. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab